Argenx Se Revenue Growth Rates (ARGX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Argenx Se  (NASDAQ: ARGX)
 

ARGX's Revenue Growth by Quarter and Year

Argenx Se's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARGX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 8,399.37
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 8,399.37

ARGXs Annual Revenue
Argenx Se's Revenue in the fiscal year 2025 $ 8,399.37 millions
Argenx Se's Revenue in the fiscal year 2024 $ 4,442.27 millions
Argenx Se's Revenue in the fiscal year 2023 $ 2,494.91 millions
Argenx Se's Revenue in the fiscal year 2022 $ 856.01 millions
Argenx Se's Revenue in the fiscal year 2021 $ 497.28 millions




ARGX Revenue fourth quarter 2025 Y/Y Growth Comment
Argenx Se reported Revenue surge of 89.08% year on year in the fourth quarter 2025, to $ 8,399.37 millions, this is lower than Argenx Se's recent average Revenue surge of 191.46%.

Looking into fourth quarter 2025 results within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Revenue growth. While Argenx Se' s Revenue jump of 89.08% ranks overall at the positon no. 40 in the fourth quarter 2025.


ARGX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 89.08 % 78.05 % 191.46 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   89.08 % 78.05 % 191.46 % -

Financial Statements
Argenx Se's fourth quarter 2025 Revenue $ 8,399.37 millions ARGX's Income Statement
Argenx Se's fourth quarter 2024 Revenue $ 4,442.27 millions Quarterly ARGX's Income Statement


ARGX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   89.08 % 78.05 % 191.46 % -


Back to ARGX Growth rate Comparisons >> Back to ARGX Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #20
Overall #40

Revenue Y/Y Growth Statistics
High Average Low
191.46 % 191.46 % 191.46 %
(Dec 31 2023)  
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #20
Overall #40
Revenue Y/Y Growth Statistics
High Average Low
191.46 % 191.46 % 191.46 %
(Dec 31 2023)  

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Argenx Se's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ARGX's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ARGX's IV. Quarter Q/Q Revenue Comment


Argenx Se's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)
Cumulative Revenue 12 Months Ending $ 8,399.37 $ 4,442.27 $ 2,494.91 $ 856.01 $ 497.28
Y / Y Revenue Growth (TTM) 89.08 % 78.05 % 191.46 % 72.14 % 1105.72 %
Year on Year Revenue Growth Overall Ranking # 40 # 66 # 132 # 0 # 0
Seqeuential Revenue Change (TTM) 89.08 % 78.05 % 191.46 % 72.14 % 1105.72 %
Seq. Revenue Growth (TTM) Overall Ranking # 40 # 66 # 131 # 0 # 0


Cumulative Revenue growth Comment
Although Argenx Se's Annual Revenue growth year on year were below company's average 191.46% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 89.08% year on year, from 78.05% in Dec 31 2024.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 40, from total ranking in previous quarter at 66.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 5
Healthcare Sector # 20
Overall # 40

Revenue TTM Y/Y Growth Statistics
High Average Low
191.46 %
 191.46 %
191.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 20
S&P 500 # 40
Cumulative Revenue growth Comment
Although Argenx Se's Annual Revenue growth year on year were below company's average 191.46% , Revenue announced in the Dec 31 2025 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 89.08% year on year, from 78.05% in Dec 31 2024.

Among companies within the Healthcare sector 19 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 40, from total ranking in previous quarter at 66.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 5
Healthcare Sector # 20
Overall # 40

Revenue TTM Y/Y Growth Statistics
High Average Low
191.46 %
191.46 %
191.46 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 5
Sector # 20
S&P 500 # 40




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARGX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2025
Nuo Therapeutics Inc 153.57%$ 153.570 millions
Anaptysbio Inc 151.08%$ 151.082 millions
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions
Lineage Cell Therapeutics Inc 130.40%$ 130.404 millions
Tarsus Pharmaceuticals Inc 128.39%$ 128.388 millions
Evaxion A125.12%$ 125.120 millions
Cybin Inc 123.74%$ 123.742 millions
Elite Pharmaceuticals Inc 119.23%$ 119.225 millions
Pavmed Inc 116.67%$ 116.667 millions
Macrogenics Inc 113.03%$ 113.032 millions
C4 Therapeutics Inc 112.79%$ 112.787 millions
Vyne Therapeutics Inc 111.90%$ 111.905 millions
Tonix Pharmaceuticals Holding Corp 108.75%$ 108.753 millions
Phathom Pharmaceuticals Inc 94.12%$ 94.121 millions
Tenon Medical Inc 92.34%$ 92.338 millions
Caribou Biosciences Inc 89.74%$ 89.745 millions
Argenx Se89.08%$ 89.078 millions
Sangamo Therapeutics Inc 88.43%$ 88.425 millions
Agios Pharmaceuticals Inc 86.09%$ 86.086 millions
Oculis Holding Ag85.72%$ 85.722 millions
Alnylam Pharmaceuticals Inc 84.95%$ 84.945 millions
Day One Biopharmaceuticals Inc 83.92%$ 83.915 millions
Neuronetics Inc 82.17%$ 82.169 millions
Arcutis Biotherapeutics Inc 81.48%$ 81.478 millions
Aclarion Inc 80.59%$ 80.590 millions
X4 Pharmaceuticals Inc79.08%$ 79.079 millions


About Argenx Se Revenue Growth Rates (ARGX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Argenx Se (CIK 1697862).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001697862-26-000032
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Argenx Se’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.